Update shared on 25 Nov 2025
Fair value Increased 8.00%Analysts have raised their price target for JD Health International from $70.25 to $75.87. This reflects improved projections for both revenue growth and profit margins.
What's in the News
- JD Health International partners with ClouDr Group Limited in a service agreement, expanding online sales and professional health management services for Remifemin and other products (Client Announcements).
- Special or Extraordinary Shareholders Meeting scheduled for December 8, 2025, at the company's Beijing headquarters (Special or Extraordinary Shareholders Meeting).
- Mr. Enlin Jin resigns as CEO effective September 29, 2025, and Mr. Dong Cao, a longtime JD executive and former CFO, is appointed as the new chief executive officer (Executive Changes, CEO).
Valuation Changes
- Fair Value: Increased from HK$70.25 to HK$75.87, reflecting an improved outlook.
- Revenue Growth: Projected to rise slightly from 15.01% to 15.18%.
- Net Profit Margin: Expected to improve from 7.06% to 7.70%.
- Discount Rate: Remains unchanged at 7.02%.
- Future P/E: Projected to decrease modestly from 36.15x to 35.49x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.